A Practical Guide to 7 High-Yield Stocks Worth Watching in 2026

Dividend Stocks and the Long-Term Reality

Dividend stocks — in the long-term — are usually not doing great regarding stock price vs. the S&P 500. That's not exactly a controversial take, but it's a truth that too many income investors conveniently overlook when they see a juicy 6% yield.

The math is simple: companies that pay out large proportions of their earnings as dividends are, by definition, reinvesting less back into growth. That shows up in price appreciation over time. The S&P 500 has returned roughly 10% annually over the last 30 years on a total return basis. The average high-dividend ETF? Significantly less, once you account for price drag.

However — and this is the key word — buying the dip can sometimes be a very good idea. When a quality dividend stock gets oversold, rates peak, or the broader market overreacts to temporary headwinds, income investors get a rare window: high yield + capital appreciation potential at the same time. That double opportunity doesn't come often. When it does, it's worth paying attention.

That's exactly why I analyzed a carefully screened set of stocks that could be worthwhile right now. The criteria were simple: sustainable dividends, strong moats, reasonable valuations, and — critically — more upside than downside from current price levels.

The Selection Criteria: What Makes a Dividend Stock Worth Buying?

Before diving into individual names, it's worth being explicit about what separates a value opportunity from a value trap. High yield alone means nothing — sometimes it just means the price has collapsed for good reason. Here's what I screened for:

• Dividend sustainability: payout ratio, free cash flow coverage, and balance sheet strength
• Moat quality: pricing power, switching costs, network effects — anything that protects earnings over time
• Valuation: trading at or below fair value on Forward P/E, P/FFO, or Price/NAV depending on sector
• Analyst conviction: majority Buy or Strong Buy ratings with meaningful upside to price targets
• Risk/reward asymmetry: best-case upside significantly outweighing worst-case downside

Seven stocks made the cut. They're spread across healthcare, real estate, infrastructure, utilities, and biotech — intentionally diversified so no single macro theme dominates.

The 7 Stocks — Ranked by Risk/Reward

The table below ranks all seven stocks by their Risk/Reward ratio — calculated as best-case upside % divided by worst-case downside %. A higher ratio means more asymmetric opportunity. Price scenarios are based on current analyst high/low targets and fundamental bear cases.

* ABBV TTM P/E shown as adjusted (~22x) stripping out one-time acquisition charges. REITs (O) best valued on P/FFO; BDCs (MAIN) on Price/NAV.

Stock-by-Stock Breakdown

🥇 1. Medtronic (MDT) — Best Risk/Reward

Yield: ~3.5%  |  Forward P/E: 16x  |  Best Case: +26%  |  Worst Case: -1%

Medtronic is the world's largest pure-play medical device maker and a Dividend Aristocrat with 46 consecutive years of dividend growth. Trading roughly 8% below Morningstar's $112 fair value estimate, it offers the most compelling asymmetric setup in this basket. The downside floor is essentially flat (-1%), while the upside to analyst high targets is +26%. For a wide-moat business with a globally diversified product portfolio and proven execution, that's an unusually attractive entry point.

🥈 2. Main Street Capital (MAIN) — Best Income Play

Yield: ~7%+  |  Forward P/E: ~15x  |  Best Case: +30%  |  Worst Case: 0%

The standout BDC. Main Street Capital has grown its monthly dividend by 136% since its 2007 IPO and regularly tops it up with supplemental quarterly payments. Internally managed (a rarity among BDCs, keeping fees low), it trades at a ~1.5x premium to NAV — justified by consistently superior returns. The worst-case scenario is essentially flat price performance, while you collect a 7%+ yield. That's a difficult combination to argue against.

🥉 3. Brookfield Infrastructure (BIP)

Yield: ~5–6%  |  Forward P/E: ~45x  |  Best Case: +11%  |  Worst Case: -5%

BIP delivered its 17th consecutive annual dividend increase in 2026, up 6%. Its cash flows are backed by long-duration, inflation-linked contracts across utilities, transportation, energy midstream, and data infrastructure spanning five continents. The high P/E reflects the long-duration nature of infrastructure assets rather than earnings richness. Modest upside but very limited downside makes this a defensive anchor in any income portfolio.

4. Realty Income (O) — The 'Monthly Dividend Company'

Yield: ~5.5%  |  P/FFO: ~12-13x  |  Best Case: +15%  |  Worst Case: -8%

Realty Income is the gold standard of net lease REITs, with 31 consecutive years of dividend increases and a $14 trillion investable market ahead of it. The company is targeting $8 billion in investments in 2026 to drive ~3% FFO per share growth. GAAP P/E overstates expensiveness for REITs — on a P/FFO basis of ~12-13x, it's reasonably valued. The -8% worst case reflects interest rate sensitivity, which is the only meaningful risk here.

5. AbbVie (ABBV) — Highest Raw Upside

Yield: ~4.5%  |  Forward P/E: 16x  |  Best Case: +29%  |  Worst Case: -21%

AbbVie has the highest raw upside in the basket (+29% to Piper Sandler's $299 target), driven by its post-Humira transition playing out better than expected. Skyrizi and Rinvoq are growing fast, and the pipeline is being actively restocked via acquisitions. The dividend has grown 330% since 2013. The -21% worst case reflects valuation risk near recent ATHs — this is a stock that rewards patience and pullback entries more than chasing.

6. Duke Energy (DUK)

Yield: ~4.2%  |  Forward P/E: 19x  |  Best Case: +9%  |  Worst Case: -12%

Duke is the quintessential boring utility — regulated revenue, predictable growth, and a multi-decade track record of dividend payments. Trading ~7% below Morningstar fair value, analysts project ~4% annual dividend growth. The -12% worst case is primarily rate-driven: if the Fed holds rates higher for longer, regulated utilities face headwinds. Best suited for conservative investors wanting predictability over excitement.

7. Gilead Sciences (GILD)

Yield: ~3.5%  |  Forward P/E: 17x  |  Best Case: +17%  |  Worst Case: -26%

Gilead is the value play with the most execution risk. Its HIV franchise is an anchor, and the recent $7.8 billion Arcellx acquisition signals serious oncology ambitions. The dividend has grown every year since 2015 (+3.8% increase in early 2026). However, the -26% bear case is real — pipeline execution risk and cautious 2026 guidance create the widest downside scenario in this basket. Only suitable for investors comfortable with biotech volatility.

Key Principles to Keep in Mind

A few things worth remembering before acting on any of the above:

• The S&P 500 average dividend yield is around just 1.2% — near a record low. Any stock paying 2× the index yield qualifies as 'high yield', but yield alone is never the investment thesis.
• With the 10-year Treasury at ~4.1%, income investors have real alternatives. Dividend stocks need to offer capital appreciation potential to compete — which is exactly why valuation matters more than usual right now.
• The ranking by Risk/Reward ratio (MDT #1, MAIN #2) is a starting point, not a trading signal. Your individual tax situation, income needs, and time horizon should drive position sizing.
• All seven stocks pay dividends that add a meaningful return cushion while waiting for price targets to be reached. Even in 'bad case' scenarios, dividend income partially offsets price declines.

⚠️ Disclaimer

This article is for informational and educational purposes only and does not constitute financial advice. All investment decisions involve risk. Past performance is not indicative of future results. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. The author may hold positions in securities mentioned.